This Small-Cap Biotech Rose as Much as 98.3% Today

Shares of Forty Seven (NASDAQ: FTSV) rose as much as 95.6% today after the company provided an encouraging update for its lead drug candidate at the Annual Meeting of the American Society of Hematology. The oddly named company is developing the monoclonal antibody magrolimab as a treatment for two rare blood disorders: myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).